N
Noel R. Dasgupta
Researcher at Indiana University
Publications - 17
Citations - 230
Noel R. Dasgupta is an academic researcher from Indiana University. The author has contributed to research in topics: Transthyretin & Amyloidosis. The author has an hindex of 5, co-authored 15 publications receiving 138 citations. Previous affiliations of Noel R. Dasgupta include Indiana University – Purdue University Indianapolis.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
TL;DR: ASO treatment of patients with moderate to advanced ATTR cardiomyopathy shows indication of stabilization of disease progression and may therefore contribute to enhanced life expectancy.
Journal ArticleDOI
Inotersen therapy of transthyretin amyloid cardiomyopathy
Noel R. Dasgupta,Stacy M. Rissing,Jessica Smith,Jeesun Jung,Merrill D. Benson,Merrill D. Benson +5 more
TL;DR: Evaluating the long term safety and efficacy of transthyretin specific antisense oligonucleotide therapy, inotersen, in tranSthyRETin cardiomyopathy found it safe and effective in inhibiting progression and potentially reversing amyloid burden.
Journal ArticleDOI
Burden of hereditary transthyretin amyloidosis on quality of life
Aaron Yarlas,Morie A. Gertz,Noel R. Dasgupta,Laura Obici,Michael L. Pollock,Elizabeth J. Ackermann,Andrew Lovley,Asia Sikora Kessler,Pankaj A. Patel,Michelle K. White,Spencer D. Guthrie +10 more
TL;DR: This study examines the impact of hATTR amyloidosis on quality of life (QOL) in patients with peripheral neuropathy, cardiomyopathy and other clinical manifestations.
Journal ArticleDOI
Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review
Mark H. Rozenbaum,Samuel Large,Rahul Bhambri,Michelle Stewart,Jo Whelan,Alexander van Doornewaard,Noel R. Dasgupta,Ahmad Masri,Jose Nativi-Nicolau +8 more
TL;DR: A targeted literature review assessed the extent and consequences of diagnostic delay and misdiagnosis in transthyretin amyloid cardiomyopathy (ATTR-CM) as mentioned in this paper.
Journal ArticleDOI
Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis.
TL;DR: Inotersen is a breakthrough therapy for treatment of ATTR and was shown to be effective in stabilizing or improving peripheral neuropathy as measured by the modified neurologic impairment score +7 (mNIS+7) and improving the quality of life assessed by the Norfolk Quality of Life-Diabetic Neuropathy questionnaire.